October 09, 2015.
Despite a record number of IPOs and a robust M&A market, the global medtech industry "continues to face tepid growth and a dwindling pool of investors for early-stage companies", according to EY's latest annual medical technology report, Pulse of the Industry. The findings raise "important questions about the long-term sustainability of the sector," Glen Giovannetti, EY's Global Life Sciences Leader, adding that, over the last 12 months, "the disparity between the ‘haves’ and the ‘have-nots’ in the medtech sector has grown increasingly stark". The report states that, over the 12-month period ending 30 June 2015, the industry saw a climate that was far from uniform and presented many challenges, including revenue and net income remaining flat; the fall of venture funding; the erosion of early-stage funding eroding; and falling innovation capital. However, the industry also delivered several strong performances. Smaller medtechs outperformed the broader medtech industry, delivering revenue and net income growth of 6% and 16%, respectively; the M&A market is "steady" and "healthy"; new financing, driven by debt and IPOs, is high; and R&D investment is rising while cash returned to shareholders decreased. Jeffrey Greene, EY’s Global Life Sciences Transactions Advisory Services Leader, commented: “At a time when the industry is continuing to experience rapid consolidation, a changing customer base, and a rise in shareholder activism, companies at all stages need to implement effective capital allocation strategies to create and demonstrate value." More more information, visit http://www.ey.com/GL/en/Industries/Life-Sciences/EY-vital-signs-pulse-medical-technology-report-2015
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.